JPRN-UMIN000019787Not yet recruiting未知
Phase 2 clinical study of neoadjuvant chemotherapy for HER2-negative primary breast cancer patients using dose dense nab-paclitaxel followed by dose dense Epirubicin and cyclophosphamide - Neoadjuvant dose-dense chemotherapy for HER2 negative breast cancer
Dept of breast oncology0 sites50 target enrollmentStarted: January 1, 2016Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 50
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 76years-old (—)
- Sex
- Female
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1) HER2 positivity 2) Previous incident of severe complication 3) Previous incident of institutional pneumonia 4) Previous incident of drug allergy 5) Active status of other cancers 6) Inflammatory breast cancer 7) Possible pregnancy
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Phase I/II-Studie zur neoadjuvanten Chemotherapie mit nicht-pegyliertem liposomalem Doxorubicin, Paclitaxel und Lapatinib bei Patientinnen mit HER2-überexprimierenden, primärem MammakarzinomeEUCTR2007-000924-42-DESana Klinikum Lichtenberg
Active, not recruiting
Not Applicable
Chemotherapy then Radiation then Immediate Curative Surgery for operable rectal cancerRectal adenocarcinomaEUCTR2010-023083-40-GBCardiff University62
Recruiting
Not Applicable
A phase II clinical trial of neoadjuvant chemoradiation therapy for pancreatic ductal adenocarcinomapancreatic cancerJPRN-UMIN000035232Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University50
Recruiting
Phase 2
A clinical phase-II trial of neoadjuvant chemoradiotherapy with S-1 and Gemcitabine for locally advanced pancreatic cancer (PerSeUS-GP02)ocally advanced pancreatic cancerJPRN-UMIN000010435PerSeUS: Perpetual Study estimated-by United Sections in gifu40
Completed
Phase 2
A clinical phase-II trial of neoadjuvant chemoradiation therapy using S-1 for locally advanced pancreatic cancer (PerSeUS-GP-01)ocally advanced pancreatic cancerJPRN-UMIN000002176PerSeUS-GP40